Cognition Therapeutics (NasdaqGM:CGTX) Q4 2025 Earnings call March 26, 2026 08:30 AM ET Company ParticipantsJohn Doyle - CFOLisa Ricciardi - President and CEOMike Moyer - Managing DirectorTony Caggiano - CMOConference Call ParticipantsDaniil Gataulin - Senior Research AnalystRaghuram Selvaraju - Managing Director and Senior Healthcare AnalystSumant Kulkarni - Biotechnology Senior AnalystWilliam Wood - Biotechnology Senior Equity Research AnalystNone - AnalystOperatorHello and welcome everyone joining today' ...

Cognition Therapeutics (NasdaqGM:CGTX) Q4 2025 Earnings call March 26, 2026 08:30 AM ET Company ParticipantsJohn Doyle - CFOLisa Ricciardi - President and CEOMike Moyer - Managing DirectorTony Caggiano - CMOConference Call ParticipantsDaniil Gataulin - Senior Research AnalystSumant Kulkarni - Biotechnology Senior AnalystWilliam Wood - Biotechnology Senior Equity Research AnalystNone - AnalystOperatorHello and welcome everyone joining today's Cognition Therapeutics fourth quarter and full year 2025 earnings ...

Cognition Therapeutics (NasdaqGM:CGTX) Q4 2025 Earnings call March 26, 2026 08:30 AM ET Speaker5Hello and welcome everyone joining today's Cognition Therapeutics fourth quarter and full year 2025 earnings call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. To register to ask a question at any time, please press star one on your telephone keypad. Please note this call is being recorded. We are standing b ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-40886 COGNITION THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4365359 (State of Other ...

-Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2025. Management wil ...

Core Viewpoint - Cognition Therapeutics, Inc. is set to release its financial results for Q4 and the full year ended December 31, 2025, on March 26, 2026, before market opening, followed by a conference call to discuss these results and provide a business update [1]. Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, aiming to provide effective therapies for conditions such as dementia with Lewy bodies, Alzheimer's disease, and Parkinson's disease [3]. - The company's lead candidate, zervimesine (CT1812), is an investigational oral therapy that has shown promise in Phase 2 clinical trials for DLB and mild-to-moderate Alzheimer's disease [3]. - The company has received nearly $200 million in grants from the National Institutes of Health and related foundations to support its clinical research efforts [3]. Conference Call Information - The conference call to discuss the financial results can be accessed by dialing (800) 445-7795 for U.S. participants or (785) 424-1699 for international participants, using conference ID number CGTXQ4 [2]. - A live webcast with Q&A will be available on the company's website, and an archive of the webcast will be accessible for 90 days starting from March 26, 2026 [2].

PURCHASE, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 COG1201 SHIMMER study (NCT05225415) of zervimesine (CT1812) in dementia with Lewy bodies (DLB) at the AD/PD™ 2026 Alzheimer's & Parkinson's Diseases Conference. The conference is being conducted March 17-21, 2026 in Copenhagen, Denmark. The analysis focuses on Ze ...

Core Viewpoint - Cognition Therapeutics is advancing the development of zervimesine for treating dementia with Lewy bodies (DLB) psychosis, which affects up to 75% of DLB patients, following positive feedback from the FDA [1][2][3] Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for age-related neurodegenerative disorders [8] - The company has completed Phase 2 studies of zervimesine in DLB and mild-to-moderate Alzheimer's disease, with ongoing studies supported by significant grants from the National Institute on Aging [8] Drug Development - Zervimesine (CT1812) is an investigational oral medication aimed at treating CNS diseases, including Alzheimer's and DLB, by interrupting the toxic effects of Aβ and ɑ-synuclein [6][7] - The Phase 2 SHIMMER study demonstrated zervimesine's positive impact on neuropsychiatric symptoms, showing an 86% slowing of decline on the neuropsychiatric inventory compared to placebo [5] Regulatory Strategy - The company plans to pursue a registrational path for zervimesine based on the strength of Phase 2 data and FDA meeting minutes, aiming to expedite its market entry [2][3] - Cognition expects to meet with the FDA Division of Psychiatry to discuss the DLB psychosis program by mid-2026 [2] Patient Impact - DLB psychosis significantly burdens patients and caregivers, leading to higher healthcare costs and earlier institutionalization, with no approved medications currently available for this condition [4] - Zervimesine has shown a favorable impact on cognitive fluctuations, memory, movement, and daily living activities without impairing motor skills, addressing a critical need for DLB patients [3]

Core Viewpoint - Cognition Therapeutics, Inc. has extended the duration of its expanded access program for dementia with Lewy bodies, allowing participants several more months of treatment beyond the initial twelve months [1]. Group 1: Expanded Access Program (EAP) - The EAP has been operational since June 2025 and aims to gather additional long-term safety data [2]. - Feedback from participants and their care partners has been favorable, highlighting the program's operational aspects that reduce travel for patients [2][3]. - A total of 32 individuals are enrolled across eight sites, each receiving 100 mg of oral zervimesine daily [2]. Group 2: Clinical Development and Regulatory Engagement - The EAP is part of a broader clinical development program for dementia with Lewy bodies, which includes the Phase 2 SHIMMER study [3]. - Cognition Therapeutics held a Type C meeting with the FDA on January 21, 2026, to discuss findings from the SHIMMER study, focusing on clinically meaningful endpoints for future studies [3]. Group 3: Company Overview - Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related neurodegenerative disorders [5]. - The company has completed Phase 2 studies for its lead candidate, zervimesine, in various conditions including dementia with Lewy bodies and mild-to-moderate Alzheimer's disease [5].

Core Insights - Cognition Therapeutics, Inc. is advancing its investigational drug zervimesine (CT1812) for treating dementia with Lewy bodies (DLB) and has conducted a Type C meeting with the FDA to discuss the Phase 2b study [1][2] Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related neurodegenerative disorders [4] - The company has completed Phase 2 studies for zervimesine in DLB and mild-to-moderate Alzheimer's disease, with ongoing studies supported by an $81 million grant from the National Institute of Aging [4] Drug Development - Zervimesine is an oral, once-daily pill aimed at treating CNS diseases, specifically targeting the toxic effects of Aβ and ɑ-synuclein proteins that contribute to neurodegeneration [2] - The drug has shown promise in interrupting the toxic effects of these proteins, potentially slowing disease progression and improving patient quality of life [2] Regulatory Engagement - The FDA meeting was described as productive, focusing on clinically meaningful endpoints for the upcoming Phase 2b study [2] - The company anticipates receiving meeting minutes from the FDA later this quarter, indicating ongoing communication to advance clinical development [2]